6.61
price down icon5.57%   -0.39
after-market Handel nachbörslich: 6.70 0.09 +1.36%
loading
Schlusskurs vom Vortag:
$7.00
Offen:
$5.86
24-Stunden-Volumen:
134.37K
Relative Volume:
3.08
Marktkapitalisierung:
$611.37M
Einnahmen:
$5.12M
Nettoeinkommen (Verlust:
$-67.00M
KGV:
-4.4966
EPS:
-1.47
Netto-Cashflow:
$-38.94M
1W Leistung:
-19.02%
1M Leistung:
+10.17%
6M Leistung:
-8.55%
1J Leistung:
-90.88%
1-Tages-Spanne:
Value
$5.86
$6.78
1-Wochen-Bereich:
Value
$5.86
$8.16
52-Wochen-Spanne:
Value
$3.816
$73.40

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name
Firmenname
Verrica Pharmaceuticals Inc
Name
Telefon
484-453-3300
Name
Adresse
10 NORTH HIGH STREET, WEST CHESTER, PA
Name
Mitarbeiter
71
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-11
Name
Neueste SEC-Einreichungen
Name
VRCA's Discussions on Twitter

Vergleichen Sie VRCA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VRCA
Verrica Pharmaceuticals Inc
6.61 64.74M 5.12M -67.00M -38.94M -1.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-06 Herabstufung H.C. Wainwright Buy → Neutral
2024-11-05 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-07-25 Hochstufung Needham Hold → Buy
2023-03-22 Eingeleitet Jefferies Buy
2023-02-13 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-05-25 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2021-05-14 Eingeleitet RBC Capital Mkts Outperform
2020-12-24 Bestätigt H.C. Wainwright Buy
2020-07-15 Herabstufung BofA Securities Buy → Neutral
2020-06-30 Bestätigt H.C. Wainwright Buy
2020-06-24 Eingeleitet Northland Capital Outperform
2020-03-24 Eingeleitet Needham Buy
2019-02-21 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten

pulisher
Jul 25, 2025

What analysts say about Verrica Pharmaceuticals Inc. stockExceptional return forecasts - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Verrica Pharmaceuticals Inc. stock priceFree Stock Selection - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is Verrica Pharmaceuticals Inc. stock overhyped or has real potentialFree Consultation - Newser

Jul 25, 2025
pulisher
Jul 24, 2025

VRCA Trading Halted: Anticipation Builds for Pending Announcemen - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

Is Verrica Pharmaceuticals Inc. stock a good hedge against inflationRemarkably fast returns - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Verrica Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit velocity - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Verrica Pharmaceuticals to implement 1-for-10 reverse stock split By Investing.com - Investing.com South Africa

Jul 23, 2025
pulisher
Jul 23, 2025

Verrica Pharmaceuticals Announces Reverse Stock Split - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Verrica Pharmaceuticals to implement 1-for-10 reverse stock split - Investing.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Verrica Pharmaceuticals Inc. a good long term investmentAccelerated earnings growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Published on: 2025-07-19 07:38:47 - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

What institutions are buying Verrica Pharmaceuticals Inc. stock nowDaily Trade Opportunity - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Verrica Pharmaceuticals Inc. stock price move sharplyInsider Strategy Insight - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - newser.com

Jul 15, 2025
pulisher
Jul 15, 2025

How Verrica Pharmaceuticals Inc. stock performs during market volatilityFree Stock Trading Community - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Average Target Price from Brokerages - Defense World

Jul 14, 2025
pulisher
Jul 10, 2025

Verrica Reports Strong Q2 Growth as YCANTH Demand Accelerates - MyChesCo

Jul 10, 2025
pulisher
Jul 10, 2025

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Down 4.9% – Should You Sell? - Defense World

Jul 10, 2025
pulisher
Jul 10, 2025

Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 09, 2025

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 | VRCA Stock News - GuruFocus

Jul 09, 2025
pulisher
Jul 09, 2025

Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales - Investing.com

Jul 09, 2025
pulisher
Jul 02, 2025

Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo

Jul 02, 2025
pulisher
Jul 01, 2025

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Commo - GuruFocus

Jul 01, 2025

Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Verrica Pharmaceuticals Inc-Aktie (VRCA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Hayes Christopher G.
CHIEF LEGAL OFFICER
Aug 26 '24
Sale
2.66
26,183
69,647
115,303
Hayes Christopher G.
CHIEF LEGAL OFFICER
Aug 27 '24
Sale
2.46
9,530
23,444
105,773
Goldenberg Gary
Chief Medical Officer
Aug 26 '24
Sale
2.66
9,888
26,302
97,862
Goldenberg Gary
Chief Medical Officer
Aug 27 '24
Sale
2.46
3,601
8,858
94,261
Bonaccorso Joe
CHIEF COMMERCIAL OFFICER
Aug 26 '24
Sale
2.66
24,709
65,726
82,107
Bonaccorso Joe
CHIEF COMMERCIAL OFFICER
Aug 27 '24
Sale
2.46
8,993
22,123
73,114
Kohler Terry
CHIEF FINANCIAL OFFICER
Aug 26 '24
Sale
2.66
21,820
58,041
52,596
Kohler Terry
CHIEF FINANCIAL OFFICER
Aug 27 '24
Sale
2.46
7,899
19,432
44,697
White Ted
PRESIDENT AND CEO
Aug 26 '24
Sale
2.66
24,979
66,444
224,988
White Ted
PRESIDENT AND CEO
Aug 27 '24
Sale
2.46
9,021
22,192
215,967
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):